[go: up one dir, main page]

MX374776B - Un método in vitro para criba de un anticuerpo anti-axl, o un fragmento de enlace del mismo, capaz de suministrar o internalizar una molécula de interés en una célula de mamífero. - Google Patents

Un método in vitro para criba de un anticuerpo anti-axl, o un fragmento de enlace del mismo, capaz de suministrar o internalizar una molécula de interés en una célula de mamífero.

Info

Publication number
MX374776B
MX374776B MX2014005244A MX2014005244A MX374776B MX 374776 B MX374776 B MX 374776B MX 2014005244 A MX2014005244 A MX 2014005244A MX 2014005244 A MX2014005244 A MX 2014005244A MX 374776 B MX374776 B MX 374776B
Authority
MX
Mexico
Prior art keywords
deliverying
internalizing
axl
screening
interest
Prior art date
Application number
MX2014005244A
Other languages
English (en)
Other versions
MX2014005244A (es
Inventor
Charlotte Beau-Larvor
Liliane Goetsch
Nicolas Boute
Original Assignee
Pierre Fabre Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Medicament filed Critical Pierre Fabre Medicament
Publication of MX2014005244A publication Critical patent/MX2014005244A/es
Publication of MX374776B publication Critical patent/MX374776B/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5035—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on sub-cellular localization
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2497—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing N- glycosyl compounds (3.2.2)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/02—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2) hydrolysing N-glycosyl compounds (3.2.2)
    • C12Y302/02022—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2) hydrolysing N-glycosyl compounds (3.2.2) rRNA N-glycosylase (3.2.2.22)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

La presente invención se refiere a una proteína de enlace de antígeno, en particular a un anticuerpo monoclonal, capaz de enlazar específicamente con la proteína Axl así como las secuencias de aminoácidos y ácidos nucleicos que codifican dicha proteína. Desde un aspecto, la invención se refiere a una proteína de enlace de antígeno, o fragmentos de enlace de antígeno, capaces de enlazarse específicamente a Axl y, al inducir la internalización de Axl, se internaliza en la célula. La invención también comprende el uso de dicha proteína de enlace de antígeno como un producto de direccionamiento en conjugación con otros compuestos anticáncer, tales como toxinas, radio - elementos o fármacos y al uso de los mismos para el tratamiento de ciertos cánceres.
MX2014005244A 2011-11-03 2012-11-05 Un método in vitro para criba de un anticuerpo anti-axl, o un fragmento de enlace del mismo, capaz de suministrar o internalizar una molécula de interés en una célula de mamífero. MX374776B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11306416.6A EP2589609A1 (en) 2011-11-03 2011-11-03 Antigen binding protein and its use as addressing product for the treatment of cancer
PCT/EP2012/071832 WO2013064684A1 (en) 2011-11-03 2012-11-05 Antigen binding protein and its use as addressing product for the treatment of cancer

Publications (2)

Publication Number Publication Date
MX2014005244A MX2014005244A (es) 2015-03-23
MX374776B true MX374776B (es) 2025-03-06

Family

ID=47116011

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014005244A MX374776B (es) 2011-11-03 2012-11-05 Un método in vitro para criba de un anticuerpo anti-axl, o un fragmento de enlace del mismo, capaz de suministrar o internalizar una molécula de interés en una célula de mamífero.
MX2014005240A MX374775B (es) 2011-11-03 2012-11-05 Proteina de union de antigeno y su uso como producto dirigido para el tratamiento del cancer.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2014005240A MX374775B (es) 2011-11-03 2012-11-05 Proteina de union de antigeno y su uso como producto dirigido para el tratamiento del cancer.

Country Status (18)

Country Link
US (3) US9689862B2 (es)
EP (3) EP2589609A1 (es)
JP (3) JP2015504302A (es)
KR (2) KR102033805B1 (es)
CN (2) CN103998468B (es)
AU (3) AU2012331068A1 (es)
BR (2) BR112014010383B1 (es)
CA (2) CA2854126A1 (es)
HK (2) HK1197073A1 (es)
IL (1) IL232342B (es)
MA (1) MA35659B1 (es)
MX (2) MX374776B (es)
MY (1) MY174259A (es)
RU (2) RU2650771C1 (es)
TN (1) TN2014000148A1 (es)
UA (1) UA119226C2 (es)
WO (2) WO2013064685A1 (es)
ZA (1) ZA201403141B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2589609A1 (en) 2011-11-03 2013-05-08 Pierre Fabre Medicament Antigen binding protein and its use as addressing product for the treatment of cancer
CN104662044B (zh) 2012-08-24 2018-10-30 加利福尼亚大学董事会 用于治疗ror1癌症并抑制转移的抗体和疫苗
ES2871815T3 (es) * 2012-11-05 2021-11-02 Pf Medicament Nuevas proteínas de unión a antígeno y su utilización como producto de direccionamiento para el tratamiento del cáncer
WO2015013579A1 (en) 2013-07-26 2015-01-29 Update Pharma Inc. Compositions to improve the therapeutic benefit of bisantrene
HUE047952T2 (hu) * 2014-04-25 2020-05-28 Pf Medicament Ellenanyag-drog konjugátum és alkalmazása rák kezelésében történõ alkalmazásra
GB201410826D0 (en) 2014-06-18 2014-07-30 Bergenbio As Anti-axl antibodies
GB201410825D0 (en) 2014-06-18 2014-07-30 Bergenbio As Anti-axl antibodies
UA127198C2 (uk) 2014-07-11 2023-06-07 Ґенмаб А/С Антитіло, яке зв'язує axl
ES2764299T3 (es) * 2014-12-09 2020-06-02 Inst Nat Sante Rech Med Anticuerpos monoclonales humanos contra AXL
MX2017007941A (es) * 2014-12-18 2018-01-30 Bergenbio Asa Anticuerpos antagonistas anti-axl.
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
JP6892431B2 (ja) 2015-07-10 2021-06-23 ゲンマブ エー／エス 癌治療用のａｘｌ特異的抗体−薬物コンジュゲート
US9669106B2 (en) 2015-10-26 2017-06-06 Pierre Fabre Medicament Conjugate of monomethyl auristatin F and trastuzumab and its use for the treatment of cancer
BR112018014277A2 (pt) 2016-01-13 2018-12-18 Genmab As formulação, e, método de preparação de uma solução injetável de um axl-adc
CN108700598A (zh) * 2016-03-25 2018-10-23 豪夫迈·罗氏有限公司 多路总抗体和抗体缀合的药物量化测定法
SG11201810355SA (en) * 2016-05-20 2018-12-28 Agency Science Tech & Res Anti-axl tyrosine kinase receptor antibodies and uses thereof
GB201610902D0 (en) 2016-06-22 2016-08-03 Bergen Teknologioverforing As And Bergenbio As Anti-Axl Antagonistic Antibodies
IL299099B1 (en) 2016-06-27 2025-03-01 Univ California Combinations of cancer treatments
KR101909955B1 (ko) * 2016-11-28 2018-10-19 재단법인 목암생명과학연구소 신규 항-에이엑스엘 항체 및 이를 포함하는 약학적 조성물
CN108456251A (zh) * 2017-02-21 2018-08-28 上海君实生物医药科技股份有限公司 抗pd-l1抗体及其应用
EP3454063B1 (de) * 2017-09-06 2022-05-18 AVA Lifescience GmbH Durchflusszytometrie-messverfahren
WO2019197506A1 (en) 2018-04-10 2019-10-17 Genmab A/S Axl-specific antibodies for cancer treatment
CN110540592B (zh) 2018-05-29 2022-08-09 杭州尚健生物技术有限公司 结合axl蛋白的抗体及其应用
TWI851577B (zh) 2018-06-07 2024-08-11 美商思進公司 喜樹鹼結合物
US20220273809A1 (en) 2019-07-19 2022-09-01 Genmab A/S Axl antibody-drug conjugates for use in treating cancer
GB201912059D0 (en) 2019-08-22 2019-10-09 Bergenbio As Combaination therapy of a patient subgroup
CN110448557A (zh) * 2019-09-05 2019-11-15 黄筱茜 抗凝血药达比加群酯的新药用途
EP4037717A1 (en) * 2019-10-04 2022-08-10 Seagen Inc. Camptothecin peptide conjugates
CN110982791A (zh) * 2019-12-26 2020-04-10 百泰生物药业有限公司 一种分泌axl抗体的杂交瘤细胞的制备筛选方法
GB202004189D0 (en) 2020-03-23 2020-05-06 Bergenbio As Combination therapy
KR20230013241A (ko) 2020-04-08 2023-01-26 베르겐바이오 에이에스에이 항바이러스 요법을 위한 axl 억제제
GB202006072D0 (en) 2020-04-24 2020-06-10 Bergenbio Asa Method of selecting patients for treatment with cmbination therapy
CN112194726B (zh) * 2020-09-02 2023-06-23 沣潮医药科技（上海）有限公司 用于病理性蛋白聚集物清除的嵌合抗原受体及其应用
GB202104037D0 (en) 2021-03-23 2021-05-05 Bergenbio Asa Combination therapy
CN113444180B (zh) * 2021-06-16 2023-03-31 上海鑫湾生物科技有限公司 靶向axl蛋白的抗体及其抗原结合片段、其制备方法和应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4970198A (en) 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
US5079233A (en) 1987-01-30 1992-01-07 American Cyanamid Company N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8924581D0 (en) 1989-11-01 1989-12-20 Pa Consulting Services Bleaching of hair
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US20110045005A1 (en) * 2001-10-19 2011-02-24 Craig Crowley Compositions and methods for the treatment of tumor of hematopoietic origin
US20040202666A1 (en) * 2003-01-24 2004-10-14 Immunomedics, Inc. Anti-cancer anthracycline drug-antibody conjugates
JP4462964B2 (ja) * 2003-03-10 2010-05-12 第一三共株式会社 癌特異的抗原を標的とした抗体
EP2286844A3 (en) * 2004-06-01 2012-08-22 Genentech, Inc. Antibody-drug conjugates and methods
NZ556055A (en) 2004-12-21 2009-12-24 Viventia Biotech Inc Cancer specific antibody and cell surface proteins
AU2007338670A1 (en) * 2006-12-22 2008-07-03 Merck Sharp & Dohme Corp. Antibodies to CD200R
CN101687924A (zh) * 2007-07-04 2010-03-31 株式会社未来创药研究所 抗Muc17抗体
KR20100097684A (ko) * 2007-11-12 2010-09-03 우드라이 파마 게엠베하 Ａｘｌ 항체
RU2559530C2 (ru) * 2007-11-15 2015-08-10 Чугаи Сейяку Кабусики Кайся Моноклональные антитела, способные связываться с белком axl, и их применение
US9011864B2 (en) 2007-12-26 2015-04-21 Biotest Ag Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates
WO2010014755A1 (en) * 2008-07-29 2010-02-04 The Regents Of The University Of Colorado Methods and compounds for enhancing anti-cancer therapy
TWI526223B (zh) * 2009-05-11 2016-03-21 Ｕ３製藥有限責任公司 人化ａｘｌ抗體類
EP2270053A1 (en) * 2009-05-11 2011-01-05 U3 Pharma GmbH Humanized AXL antibodies
WO2011014457A1 (en) * 2009-07-27 2011-02-03 Genentech, Inc. Combination treatments
US20120282173A1 (en) 2009-08-17 2012-11-08 Forerunner Pharma Research Co., Ltd. Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient
US8926976B2 (en) * 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
CA3056999A1 (en) * 2010-01-22 2011-07-28 Amato J. Giaccia Inhibition of axl signaling in anti-metastatic therapy
KR20140104944A (ko) * 2011-06-22 2014-08-29 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 항-ａｘｌ 항체 및 그의 용도
EP2589609A1 (en) * 2011-11-03 2013-05-08 Pierre Fabre Medicament Antigen binding protein and its use as addressing product for the treatment of cancer
WO2014174111A1 (en) * 2013-04-26 2014-10-30 Pierre Fabre Medicament Axl antibody-drug conjugate and its use for the treatment of cancer

Also Published As

Publication number Publication date
HK1197073A1 (en) 2015-01-02
WO2013064685A1 (en) 2013-05-10
TN2014000148A1 (en) 2015-09-30
WO2013064684A1 (en) 2013-05-10
JP2018052970A (ja) 2018-04-05
MY174259A (en) 2020-04-01
IL232342A0 (en) 2014-06-30
RU2659094C2 (ru) 2018-06-28
KR20140091035A (ko) 2014-07-18
AU2012331069B2 (en) 2017-01-05
US20150037340A1 (en) 2015-02-05
US20160131639A1 (en) 2016-05-12
ZA201403141B (en) 2015-04-29
US9173962B2 (en) 2015-11-03
AU2017219091A1 (en) 2017-09-21
CA2851941C (en) 2021-01-12
CN104039829A (zh) 2014-09-10
UA119226C2 (uk) 2019-05-27
KR20140094589A (ko) 2014-07-30
KR102089114B1 (ko) 2020-04-14
MA35659B1 (fr) 2014-11-01
MX2014005240A (es) 2014-08-22
JP2015504302A (ja) 2015-02-12
AU2012331069A1 (en) 2014-06-05
IL232342B (en) 2021-03-25
MX2014005244A (es) 2015-03-23
US10161930B2 (en) 2018-12-25
JP6345595B2 (ja) 2018-06-20
US20140141023A1 (en) 2014-05-22
US9689862B2 (en) 2017-06-27
EP2589609A1 (en) 2013-05-08
AU2017219091B2 (en) 2019-05-02
BR112014010383B1 (pt) 2022-02-01
NZ624989A (en) 2016-08-26
RU2650771C1 (ru) 2018-04-17
AU2012331068A1 (en) 2014-05-22
KR102033805B1 (ko) 2019-10-17
BR112014010383A2 (pt) 2017-04-25
EP2773663A1 (en) 2014-09-10
RU2014120629A (ru) 2015-12-10
CN103998468A (zh) 2014-08-20
EP2773666A1 (en) 2014-09-10
BR112014010591A2 (pt) 2017-05-02
CA2854126A1 (en) 2013-05-10
JP6685270B2 (ja) 2020-04-22
JP2014532687A (ja) 2014-12-08
CN103998468B (zh) 2017-04-19
MX374775B (es) 2025-03-06
CA2851941A1 (en) 2013-05-10
CN104039829B (zh) 2021-01-08
HK1199460A1 (en) 2015-07-03

Similar Documents

Publication Publication Date Title
MX374776B (es) Un método in vitro para criba de un anticuerpo anti-axl, o un fragmento de enlace del mismo, capaz de suministrar o internalizar una molécula de interés en una célula de mamífero.
MX2021002144A (es) Anticuerpo igf-1r y su uso como un vehiculo con especificidad de objetivo para el tratamiento contra el cancer.
AR093357A1 (es) Proteinas de union al antigeno y su utilizacion como producto de direccionamiento para el tratamiento del cancer
CY1119539T1 (el) Πληρως ανθρωπινα αντισωματα ειδικα για to cadμ1
WO2010009124A3 (en) Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
MX366965B (es) Moleculas de anticuerpos biespecificos con celulas t transfectadas por antigeno y su uso en medicina.
MX378807B (es) Inmunotoxinas de union a cd20 para inducir internalizacion celular y metodos que usan las mismas.
UA95068C2 (uk) Антиген-зв'язуюча молекула, яка зв'язує еgfr, вектор, що її кодує, та їх застосування
TN2014000120A1 (en) Cd27l antigen binding proteins
IN2009KN02404A (es)
MX351502B (es) Anticuerpos de union de albumina y fragmentos de union de los mismos.
MX2018008680A (es) Moleculas de union especifica a proteina de union a adn de respuesta transactiva de 43 kda (tdp-43).
MX2014015830A (es) Anticuerpos lsr y usos de los mismos para el tratamiento de cancer.
BR112015023418A2 (pt) conjugado de anticorpo e fármaco, anticorpo ou fragmento de ligação de antígeno, seus processos de produção, seus usos, ácido nucleico, vetor, e célula hospedeira
PH12014500932A1 (en) Antibodies specific for trop-2 and their uses
MX2010003581A (es) Anticuerpos humanos que se adhieren a mesotelina, y usos de los mismos.
EP4406612A8 (en) Anti-cd70 antibody drug conjugates
MX2010005830A (es) Conjugado de anticuerpo monoclonal anti-b7h4 - farmaco y metodos de uso del mismo.
EP3009454A3 (en) Antibodies specific to cadherin-17
TH146212A (th) โปรตีนเข้าจับแอนติเจนและการใช้ของมันในฐานะเป็นผลิตภัณฑ์แก้ปัญหาสำหรับการบำบัดมะเร็ง
UA97414C2 (ru) Выделенное человеческое антитело, связывающееся с gm-csf

Legal Events

Date Code Title Description
FG Grant or registration